Literature DB >> 3372029

Single and multiple dose pharmacokinetics of ciprofloxacin in gynecological tissues.

G J Gerstner1, A Dalhoff, H Weuta.   

Abstract

In a prospective pharmacokinetic study the serum and tissue concentrations of ciprofloxacin (Bay O9867), a new carboxyquinolone antimicrobial agent were studied. 22 patients were given 300 mg ciprofloxacin i. v. before the operation (group A), and 19 patients were premedicated with 500 mg ciprofloxacin orally twice daily for three days followed by 300 mg i. v. preoperatively. Tissue samples weighing approximately 2 g were taken from the fallopian tubes, the ovaries, the fundus myometrium and the cervix. Ciprofloxacin concentrations were measured biologically by the cup plate agar diffusion method. Ciprofloxacin concentrations in serum and gynecological tissues were within the same range in both groups. Maximal serum concentrations of 6 and 4 mg/l, respectively, were recorded immediately after infusion. After 2 h serum concentrations ranged from 0.6 to 1.3 mg/l in both groups. At the same time, the tissue concentrations ranged from 0.62 to 3.3 mg/kg, indicating that tissue levels exceed corresponding serum concentrations. On average ciprofloxacin is concentrated in the extravascular space two-fold, as compared to the corresponding serum concentrations. There is no drug accumulation. The tissue concentrations obtained provide a full antibacterial coverage for gynecological infections, since the MIC for the most pathogenic bacteria is less than 1 mg/l.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3372029     DOI: 10.1007/bf01650503

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  13 in total

1.  Pharmacokinetics of intravenously administered ciprofloxacin.

Authors:  R Wise; R M Lockley; M Webberly; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

2.  Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers.

Authors:  E Klinge; P T Männistö; R Mäntylä; J Mattila; U Hänninen
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

3.  Pharmacokinetic model for nalidixic acid in man. 3. Effect of repeated oral dosage.

Authors:  E W McChesney; G A Portmann; R F Koss
Journal:  J Pharm Sci       Date:  1967-05       Impact factor: 3.534

4.  Multiple-dose ciprofloxacin kinetics in normal subjects.

Authors:  G E Aronoff; C H Kenner; R S Sloan; S T Pottratz
Journal:  Clin Pharmacol Ther       Date:  1984-09       Impact factor: 6.875

5.  Levels of trimethoprim and sulfamethoxazole in human oviduct mucosa and plasma.

Authors:  C Brihmer; J Brundin; K Dornbusch
Journal:  Acta Obstet Gynecol Scand       Date:  1982       Impact factor: 3.636

6.  Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

Authors:  W Wingender; K H Graefe; W Gau; D Förster; D Beermann; P Schacht
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

7.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration.

Authors:  G Höffken; H Lode; C Prinzing; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

8.  Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.

Authors:  M A Gonzalez; F Uribe; S D Moisen; A P Fuster; A Selen; P G Welling; B Painter
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

9.  Ciprofloxacin concentrations in tonsils following a single intravenous infusion.

Authors:  N Falser; A Dalhoff; H Weuta
Journal:  Infection       Date:  1984 Sep-Oct       Impact factor: 3.553

10.  Comparative in vitro studies with 4-quinolone antimicrobials.

Authors:  D Felmingham; M D O'Hare; M J Robbins; R A Wall; A H Williams; A W Cremer; G L Ridgway; R N Grüneberg
Journal:  Drugs Exp Clin Res       Date:  1985
View more
  1 in total

Review 1.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.